Thera-SAbDab

EPRATUZUMAB

>   Structural Summary
TherapeuticEpratuzumab
TargetCD22
Heavy ChainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS
Light ChainDIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv Structure5vkk [Fvs: AB, HL], 5vl3 [Fvs: AB, CD, EF, HL]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Epratuzumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 101 102 103 104 105 106 107 108 109 110 111 112 113
epratuzumab Q V Q L V Q S G A E V K K P G S S V K V S C K A S G Y T F T S Y W L H W V R Q A P G Q G L E W I G Y I N P R N D Y T E Y N Q N F K D K A T I T A D E S T N T A Y M E L S S L R S E D T A F Y F C A R R D I T T F Y W G Q G T T V T V S S
5vl3 Q V Q L V Q S G A E V K K P G S S V K V S C K A S G Y T F T S Y W L H W V R Q A P G Q G L E W I G Y I N P R N D Y T E Y N Q N F K D K A T I T A D E S T N T A Y M E L S S L R S E D T A F Y F C A R R D I T T F Y W G Q G T T V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 30B 30C 30D 30E 30F 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 96 97 98 99 100 101 102 103 104 105 106 107
epratuzumab D I Q L T Q S P S S L S A S V G D R V T M S C K S S Q S V L Y S A N H K N Y L A W Y Q Q K P G K A P K L L I Y W A S T R E S G V P S R F S G S G S G T D F T F T I S S L Q P E D I A T Y Y C H Q Y L S S W T F G G G T K L E I K
5vl3 D I Q L T Q S P S S L S A S V G D R V T M S C K S S Q S V L Y S A N H K N Y L A W Y Q Q K P G K A P K L L I Y W A S T R E S G V P S R F S G S G S G T D F T L T I S S L Q P E D I A T Y Y C H Q Y L S S W T F G G G T K L E I K
Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 101 102 103 104 105 106 107 108 109 110 111 112 113
epratuzumab Q V Q L V Q S G A E V K K P G S S V K V S C K A S G Y T F T S Y W L H W V R Q A P G Q G L E W I G Y I N P R N D Y T E Y N Q N F K D K A T I T A D E S T N T A Y M E L S S L R S E D T A F Y F C A R R D I T T F Y W G Q G T T V T V S S
5vkk Q V Q L V Q S G A E V K K P G S S V K V S C K A S G Y T F T S Y W L H W V R Q A P G Q G L E W I G Y I N P R N D Y T E Y N Q N F K D K A T I T A D E S T N T A Y M E L S S L R S E D T A F Y F C A R R D I T T F Y W G Q G T T V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 30B 30C 30D 30E 30F 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 96 97 98 99 100 101 102 103 104 105 106 107
epratuzumab D I Q L T Q S P S S L S A S V G D R V T M S C K S S Q S V L Y S A N H K N Y L A W Y Q Q K P G K A P K L L I Y W A S T R E S G V P S R F S G S G S G T D F T F T I S S L Q P E D I A T Y Y C H Q Y L S S W T F G G G T K L E I K
5vkk D I Q L T Q S P S S L S A S V G D R V T M S C K S S Q S V L Y S A N H K N Y L A W Y Q Q K P G K A P K L L I Y W A S T R E S G V P S R F S G S G S G T D F T L T I S S L Q P E D I A T Y Y C H Q Y L S S W T F G G G T K L E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed1999
INN Year Recommended2000
Companies InvolvedCharite - Universitatsmedizin Berlin, Children's Oncology Group, Immunomedics, National Cancer Institute (USA), UCB
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedPrecursor cell lymphoblastic leukaemia-lymphoma, Systemic lupus erythematosus, Non-Hodgkin's lymphoma, Cachexia
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]